{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:27:14Z","timestamp":1779290834636,"version":"3.51.4"},"reference-count":18,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"unspecified","delay-in-days":139,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["ESR-23-22154"],"award-info":[{"award-number":["ESR-23-22154"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2026,4,9]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Direct oral anticoagulants (rivaroxaban, apixaban, dabigatran) and warfarin treatment are associated with an increased risk of intracerebral haemorrhage (ICH). Specific reversal exists for warfarin (vitamin K\/prothrombin complex concentrate (PCC)) and dabigatran (idarucizumab). Data on protocol-guided non-specific 3-factor PCC for factor Xa inhibitor reversal are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Our retrospective cohort study aimed to assess anticoagulation-related ICH secular trends. We also aimed to compare administration of reversal and antihypertensive treatments, where specific reversal agents were (dabigatran and warfarin) and were not (apixaban and rivaroxaban) available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included patients with anticoagulation-related non-traumatic ICH of &lt;24\u2009hours duration from South Australian Stroke units (January 2017\u2013December 2023). Outcomes analysed included 30-day mortality and discharge modified Rankin Scale. Secondary outcomes included time to administration of reversal agent, intravenous antihypertensives and time to systolic blood pressure (BP) lowering &lt;140\u2009mm Hg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 310 included patients (median age 83 (76, 87)), 208 (67%) were in the factor Xa inhibitor group and 102 (33%) in the warfarin\/dabigatran group. The proportion of factor Xa inhibitor-associated ICH increased from 3.7% in 2017 to 19.8% in 2023 (p&lt;0.0001). The warfarin\/dabigatran group was more likely to receive reversal (57% warfarin\/dabigatran vs factor Xa inhibitor 39%, p=0.005). Where administered, time from hospital arrival to reversal did not differ between groups (132\u2009min (94, 231) warfarin\/dabigatran vs factor Xa inhibitor 126 (60, 225); p=0.3), nor did time to first dose of intravenous antihypertensives, time to BP &lt;140\u2009mm Hg and 30-day mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Factor Xa inhibitor-related ICH increased proportionally over the study period. These patients were less likely to receive reversal treatment than warfarin\/dabigatran-related ICH. There was no difference between time to administration of PCC and time to antihypertensive metrics. The high mortality in our study underscores the need for effective optimised and timely treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2025-001239","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:35:25Z","timestamp":1779287725000},"page":"e001239","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Anticoagulation associated intracerebral haemorrhage trends, treatment and outcomes in a metropolitan cohort: analysed by availability of specific versus non-specific reversal agents"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5264-5885","authenticated-orcid":false,"given":"Shaddy","family":"El-Masri","sequence":"first","affiliation":[{"name":"Department of Neurology, Flinders Medical Centre, Bedford Park, South Australia, Australia"},{"name":"Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudy","family":"Goh","sequence":"additional","affiliation":[{"name":"Royal Adelaide Hospital, Adelaide, South Australia, Australia"},{"name":"The University of Adelaide, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Bacchi","sequence":"additional","affiliation":[{"name":"Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia"},{"name":"The University of Adelaide, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lachlan","family":"Tamlin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Flinders Medical Centre, Bedford Park, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Sulley-Beales","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Howson","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Stretton","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia"},{"name":"The University of Adelaide, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Zweck","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Willcourt","sequence":"additional","affiliation":[{"name":"Department of Neurology, Flinders Medical Centre, Bedford Park, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Moey","sequence":"additional","affiliation":[{"name":"Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"Jannes","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4430-3276","authenticated-orcid":false,"given":"Timothy","family":"Kleinig","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia"},{"name":"The University of Adelaide, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"2026052007351808000_8.1.e001239.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007432"},{"key":"2026052007351808000_8.1.e001239.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"2026052007351808000_8.1.e001239.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"2026052007351808000_8.1.e001239.4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.37438","article-title":"Clinical Characteristics and Outcomes Associated With Oral Anticoagulant Use Among Patients Hospitalized With Intracerebral Hemorrhage","volume":"4","author":"Xian","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026052007351808000_8.1.e001239.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313040"},{"key":"2026052007351808000_8.1.e001239.6","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S1474-4422(16)00110-1","article-title":"Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial","volume":"15","author":"Steiner","year":"2016","journal-title":"Lancet Neurol"},{"key":"2026052007351808000_8.1.e001239.7","doi-asserted-by":"crossref","DOI":"10.1002\/emp2.12655","article-title":"Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding","volume":"3","author":"Cohen","year":"2022","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"2026052007351808000_8.1.e001239.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-782060"},{"key":"2026052007351808000_8.1.e001239.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707278"},{"key":"2026052007351808000_8.1.e001239.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.0846"},{"key":"2026052007351808000_8.1.e001239.11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026723","article-title":"Trends in Oral Anticoagulant Use Among 436\u2009864 Patients With Atrial Fibrillation in Community Practice, 2011 to 2020","volume":"11","author":"Navar","year":"2022","journal-title":"JAHA"},{"key":"2026052007351808000_8.1.e001239.12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54916","article-title":"Prothrombin Complex Concentrate vs Conservative Management in ICH Associated With Direct Oral Anticoagulants","volume":"7","author":"Ip","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026052007351808000_8.1.e001239.13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamaneurol.2024.0221","article-title":"Time to Anticoagulation Reversal and Outcomes After Intracerebral Hemorrhage","volume":"81","author":"Sheth","year":"2024","journal-title":"JAMA Neurol"},{"key":"2026052007351808000_8.1.e001239.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09536-1"},{"key":"2026052007351808000_8.1.e001239.15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(23)00806-1","article-title":"The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial","volume":"402","author":"Ma","year":"2023","journal-title":"The Lancet"},{"key":"2026052007351808000_8.1.e001239.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314741"},{"key":"2026052007351808000_8.1.e001239.17","doi-asserted-by":"crossref","first-page":"XLVIII","DOI":"10.1177\/23969873211012133","article-title":"European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage","volume":"6","author":"Sandset","year":"2021","journal-title":"Eur Stroke J"},{"key":"2026052007351808000_8.1.e001239.18","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.123.043033"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2025-001239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:35:27Z","timestamp":1779287727000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2025-001239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,5,20]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjno-2025-001239"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2025-001239","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}